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Background: There is growing evidence of a relationship between nutrients and muscle mass, strength,
and physical performance. Although nutrition is seen as an important pillar of treating sarcopenia, data
on the nutritional intake of sarcopenic older adults are limited.
Objective: To investigate potential nutritional gaps in the sarcopenic population, the present study compared
nutrient intake and biochemical nutrient status between sarcopenic and nonsarcopenic older adults.
Design: The Maastricht Sarcopenia Study included 227 community-dwelling older adults (65 years)
from Maastricht, 53 of whom were sarcopenic based on the European Working Group on Sarcopenia in
Older People algorithm. Habitual dietary intake was assessed with a food frequency questionnaire and
data on dietary supplement use were collected. In addition, serum 25-hydroxyvitamin D, magnesium
and a-tocopherol/cholesterol, plasma homocysteine and red blood cell n-3, and n-6 fatty acids proﬁles
were assessed. Nutrient intake and biochemical nutrient status of the sarcopenic groups were compared
with those of the nonsarcopenic groups. The robustness of these results was tested with a multiple
regression analysis, taking into account between-group differences in characteristics.
Results: Sarcopenic older adults had a 10%e18% lower intake of 5 nutrients (n-3 fatty acids, vitamin B6,
folic acid, vitamin E, magnesium) compared with nonsarcopenic older adults (P < .05). When taking into
account dietary supplement intake, a 19% difference remained for n-3 fatty acids intake (P ¼ .005). For
the 2 biochemical status markers, linoleic acid and homocysteine, a 7% and 27% difference was observed,
respectively (P < .05). The higher homocysteine level conﬁrmed the observed lower vitamin B intake in
the sarcopenic group. Observed differences in eicosapentaenoic acid and 25-hydroxyvitamin D between
the groups were related to differences in age and living situation.
Conclusions: Sarcopenic older adults differed in certain nutritional intakes and biochemical nutrient
status compared with nonsarcopenic older adults. Dietary supplement intake reduced the gap for some
of these nutrients. Targeted nutritional intervention may therefore improve the nutritional intake and
biochemical status of sarcopenic older adults.
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and Long-Term Care Medicine. PuThe average age of the world’s population is rapidly increasing.
The United Nations estimates that from 2015 to 2050, the proportion
of adults aged 65 years and older will increase from 8% to 16%.1 With
the increased life expectancy, the number of older adults who are
care-dependent will also rise, with an expected 4-fold increase by
2050.2 This emphasizes the importance of promoting healthy aging,
adding quality to the years lived, and prolonging independence and
aging in place.blished by Elsevier Inc. This is an open access article under the CC BY-NC-ND license
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copenia.3 The geriatric syndrome sarcopenia is deﬁned by the Eu-
ropean Working Group on Sarcopenia in Older People, as the loss of
muscle mass, strength, and physical performance.4 Based on this
deﬁnition, up to 29% of community-dwelling older adults are sar-
copenic.5 Multiple risk factors are identiﬁed for sarcopenia, including
among others, physical inactivity, chronic diseases, malnutrition, and
low protein intake.3
Nutrition, and nutrition in combination with exercise, are seen as
important pillars for the treatment and prevention of sarcopenia, and an
optimal quantity and quality of dietary protein and adequate 25-
hydroxyvitamin D levels are recommended by international soci-
eties.6,7 In addition to protein and vitamin D, the B vitamins, antioxidants
and omega 3 fatty acids have been found to be related to sarcopenia
determinants (ie, muscle mass, strength, and physical performance).8,9
Only a few studies have assessed the dietary intake of sarcopenic
older adults. The Korea National Health and Nutrition Examination
Survey (KNHANES) cohort observed a lower energy, protein, carbo-
hydrate, and calcium intake among sarcopenic older adults.10,11
Adhering to a Mediterranean diet was found to be inversely associ-
ated with sarcopenia in Iranian older adults.12
The aim of the present study was to provide a comprehensive
assessment of the nutrient intake and biochemical nutrient status of
Dutch sarcopenic older adults, and to investigate if there are nutri-
tional differences compared with nonsarcopenic older adults. Data
from the Maastricht Sarcopenia Study (MaSS)13 were used.
Methods
MaSS (clinicaltrials.gov #NCT01820988) is a cross-sectional study in
which the characteristics, prevalence, and consequences of sarcopenia
were assessed in community settings. For details on the study design
and sarcopenia assessment see the original publication by Mijnarends
et al.13 In short, participants were recruited from May 2013 to March
2014 in Maastricht, The Netherlands. Older adults (aged 65 years)
were eligible if they were living at home with or without professional
home care, or living in an assisted or residential living facility and had
an understanding of the Dutch language. In total 247 home visits were
performed. Assessments took place during a 1- to 2-hour home visit,
following standardized protocols. Older adults were excluded if they
had a cognitive function (Mini-Mental State Examination (MMSE))14
score <24, or if the assessments could not be performed (ie, pros-
thesis, pacemaker, wheelchair bound or bedridden, severe active
rheumatoid arthritis, acute angina pectoris, poststroke status with
evident lingering symptoms, diseases of the nervous system, or de-
mentia). Informed consent was obtained from all participants, and
ethics approval was obtained from theMedical Ethics Committee of the
Academic Hospital Maastricht and Maastricht University.
Participant Characteristics
During the home visit, the following participant characteristics
were obtained via a questionnaire: sex, age, living situation, cognitive
function (MMSE), ethnicity, smoking status, alcohol use, and comor-
bidities (Charlson Comorbidity Index15). Body height and weight were
assessed with a stadiometer (SECA 213, Seca, Hamburg, Germany) and
scale (SECA 877), respectively. Body mass index (BMI) was calculated
as weight in kg divided by height in m2. In addition, information was
collected on physical activity with the Minnesota Leisure Time Phys-
ical Activity Questionnaire.16,17
Assessment of Sarcopenia
Sarcopenia was assessed following the European Working Group
on Sarcopenia in Older People algorithm,4 including low muscle massand poor grip strength and/or slow gait speed. In short, muscle mass
was assessed after an overnight fast, by using bio-electrical impedance
(Aker BIA 50 kHz; Akern Srl, Florence, Italy).18 Skeletal muscle mass
(SMM) was calculated based on the Janssen equation.19 Skeletal
muscle index (SMI) was calculated as SMM divided by height in m2.
Muscle mass was considered low if SMI 10.75 kg/m2 in men and
6.75 kg/m2 in women,20 thereby including both severe and moder-
ate sarcopenia. Muscle strength was assessed with the Jamar hand-
held dynamometer (Sammons Preston, Inc, Warrenville, IL). Three
attempts were performed per hand, with alternating the left and right
hand. The best attempt, the maximum grip strength, was used as the
outcome measure. Muscle strength was deﬁned as poor if <20 kg in
women and <30 kg in men.21 Gait speed was measured during a 4-
meter walk test and considered slow if 0.8 m/s.4,21,22
Energy and Nutrient Intake and Malnutrition Assessment
Habitual dietary intake was assessed with the food frequency
questionnaire (FFQ) FQ29, which contains 67 questions and 104 items.
The FQ29 was generated by the validated Dutch FFQ-TOOL.23 The
Dutch food composition table of 201024 was used for calculating the
nutrient intake per day. Portion sizes were based on standard
weights.25 The FQ29 assesses dietary intakes of energy, carbohydrates,
protein, fat, total n-3 fatty acids [sumof a-linolenic acid (ALA,18:3n-3),
18:4n-3, 20:3n-3, 20:4n-3, eicosapentaenoic acid (EPA, 20:5n-3),
22:3n-3, docosapentaenoic acid (DPA, 22:5n-3), and docosahexaenoic
acid (DHA, 22:6n-3)], ALA, EPA, DHA, alcohol, calcium, magnesium,
zinc, selenium, vitamins B6, B12, C, D, E, and folic acid equivalents. These
nutrients were selected based on previous studies indicating associa-
tionsbetween thesenutrients and thedeterminantsof sarcopenia.26e32
In order to test the feasibility of the full set ofMaSS assessments, a pilot
study was performed in 8 older adults [assisted living (n ¼ 4), resi-
dential living facility (n ¼ 4)].33,34 Based on this pilot study, it was
decided to add an example page to the FFQ to increase the compre-
hensibility. Study participants were asked to ﬁll in the paper version of
the FFQ before the study visit. During the visit, the FFQwas checked for
completeness, and additional information was added by the re-
searchers if needed. Data were entered in the online FFQ-TOOL by 2
researchers, and a full data entry checkwas performedbya nutritionist.
Dietary supplement intake was recorded separately, including details
on supplement name, dose, and composition. From here on the term
“dietary intake” will comprise the results from the FFQ, whereas
“nutrient intake” includes the total intake: the sum of the dietary and
supplement intake. The Mini Nutritional Assessment Short-Form
(MNA-SF)35,36 was used to determine the presence of malnutrition.
Biochemical Markers of Nutrient Status
Blood samples were collected during the home visit, after an
overnight fast. The following biochemical markers were assessed:
25-hydroxyvitamin D, magnesium, red blood cell (RBC) n-3, and n-6
fatty acid proﬁle. TheRBC fattyacid proﬁleswereused todetermine the
percentage of total n-3, total n-6, EPA, DPA, DHA, linoleic acid (LA,
18:2n-6) and arachidonic acid (AA, 20:4n-6). The sum score of n-3 fatty
acids was deﬁned as the sum of ALA, 18:4n-3, 20:3n-3, EPA, 22:3n-3,
DPA, and DHA. The sum score of n-6 fatty acids was deﬁned as the sum
of LA,18:3n-6, 20:2n-6, 20:3n-6, AA, 22:4n-6, 22:5n-6, and 24:2n-6. As
a marker for antioxidant status, a-tocopherol levels were assessed and
corrected for cholesterol. Plasma homocysteine was measured as an
indirect status marker for B vitamins B6, B12 and folate. Blood was
collected in ethylenediaminetetraacetic acid-containing tubes for
analysis of the lipid proﬁle, in serum tubes for analysis of
25-hydroxyvitamin D, magnesium, a-tocopherol and cholesterol, and
in Sarstedt tubes for the analysis of homocysteine. Blood sampleswere
centrifuged directly following the home visits. RBCs were washed
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25-hydroxyvitamin D concentration was determined with the chem-
iluminescence IDS-iSYS 25-Hydroxy Vitamin Ds assay
(Immunodiagnostic Systems Ltd, Boldon, England). Serum
magnesium was determined photometrically with Magnesium Gen.2
(COBAS, Roche Diagnostics GmbH, Mannheim, Germany). Lipids were
extracted from RBCs and were assessed qualitatively as percentage of
the total lipid fraction, with gas chromatography (Shimadzu Benelux,
’s-Hertogenbosch, The Netherlands). Serum a-tocopherol was
assessed with ultra-fast liquid chromatography (Shimadzu Benelux).
Cholesterol was assessed with the colorimetric method Cholesterol
Gen.2 (COBAS, Roche Diagnostics GmbH). Plasma homocysteine, was
analysed with a Quattro Premier tandem mass spectrometer (Waters
Chromatography B.V., Etten-Leur, The Netherlands).
Data Analyses
For data interpretation, energy and nutrient intakes were
compared with the nutritional reference values and data from existing
cohorts. For a complete overview of the nutritional reference values
used see Appendix Table A1. The nutritional reference values were
selected based on the most recent recommendations in the following
order: (1) the Dutch Health Council, (2) the Nordic Nutrition Recom-
mendations; and (3) European Food Safety Authority, as advised by
The Netherlands Nutrition Center Foundation.37 The acceptable
macronutrient distribution range (AMDR) and the estimated average
requirement (EAR) were used. If an EAR was not stated, the adequate
intakewas used. A MNA-SF score of 0e7 was considered to represent
malnutrition, 8e11 risk of malnutrition, and 12e14 no malnutrition.35
Serum magnesium levels were considered deﬁcient if below
0.75 mmol/L.38 Serum a-tocopherol levels were considered low if the
a-tocopherol-cholesterol ratio was below 2.25 mmol/mmol.39 Serum
25-hydroxyvitamin D levels below 50 nmol/L were considered deﬁ-
cient.40 Plasma homocysteine levels above 15 mmol/L were considered
above the normal physiological range38,41 and indicated low levels of
vitamins B6, B12 and/or folate.
Comparisons between groups were made using the 2 independent
samples t-test. The Shapiro-Wilks test with alpha 0.01 was used to
determine if the distribution of continuous variables deviated from
the normal distribution in which case the nonparametric Wilcoxon
rank sum test was used. For categorical variables, comparisons be-
tween groups were made using the c2 test. Multiple regression ana-
lyses were used, taking possible covariates into account, thereby
determining whether the nutrient intake and biochemical nutrient
status differences between the groups were indeed related to sarco-
penia and not to other participant characteristics. The following
covariates were included for the evaluation of dietary and nutrient
intake: age, sex, MNA-SF score and malnutrition category, living-
situation, ethnicity, smoking status, alcohol drinking status and
amount of alcohol consumed, MMSE, comorbidities, weight, height,
BMI, physical activity, and energy intake. For the biochemical nutrient
status, in addition, dietary supplement use was included as a covari-
ate. The multiple regression analysis were performed by including all
covariates in 1 model, followed by an analysis in which the covariates
were tested one by one in separate models. Based on the results,
subsequent subgroup analyses (for age categories and living situa-
tions) were performed by 1-way analysis of variance and Tukey all-
pairs comparison. Results were considered statistically signiﬁcant
when the P value was <.05. Analyses were performed in SAS Enter-
prise Guide v 4.3 (SAS Institute Inc., Cary, NC).
Results
In total, 227 participants had complete data sets andwere included
in the analysis. For the ﬂow diagram on participant selection seeFigure 1. Participants without FFQ data (n ¼ 1) or when no blood
sample was available (n ¼ 1) were excluded from the intake and
biochemical status analysis, respectively. Population characteristics
and differences between the sarcopenic and nonsarcopenic groups are
shown in Table 1. Fifty-three participants (23%) were identiﬁed as
being sarcopenic. The median age of the MaSS participants was
74 years, with the sarcopenic group being signiﬁcantly older than the
nonsarcopenic participants (81 vs 72 years of age, respectively,
P < .001). Of the MaSS population, 9% was at risk of malnutrition and
1% was malnourished, with no signiﬁcant difference in the MNA-SF
categories between the sarcopenic and nonsarcopenic (P ¼ .194).
Although theMNA-SF score was signiﬁcantly different between the 2
groups (P¼ .039), both groups had amedian score at the upper limit of
14. The sarcopenic older adults lived more frequently in a care
providing setting (P < .01), had a higher number of comorbidities
(P < .001), and a lower MMSE score (P ¼ .003). Median MMSE score
was however near the maximum of 30 in both the sarcopenic and
nonsarcopenic group. Body height (P ¼ .007), weight (P ¼ .002), and
BMI (P ¼ .048), were lower in the sarcopenic older adults compared
with the nonsarcopenic older adults. The difference between the
groups in sarcopenia status was conﬁrmed by signiﬁcantly lower SMM
(P ¼ .003), SMI (P ¼ .020), handgrip strength (P < .001), gait speed
(P < .001), and physical activity (P < .001) in the sarcopenic group.
Dietary and Nutrient Intake
The dietary and nutrient intakes of the total MaSS population and
the sarcopenic and nonsarcopenic groups are shown in Table 2. Sar-
copenic and nonsarcopenic group comparisons were made for both
dietary intake and nutrient intake. Overall, dietary supplement use
seemed less in the sarcopenic older adults compared with the non-
sarcopenic older adults (34% vs 42%, respectively), although this dif-
ference was not statistically signiﬁcant. When considering dietary
intake only, signiﬁcant lower intakes were found between sarcopenic
and nonsarcopenic groups for protein (g/d), n-3 fatty acids, ALA,
vitamin B6, folic acid equivalents, vitamin E, magnesium, and sele-
nium. Vitamin D intake was lower in the sarcopenic group, although
not signiﬁcant (P ¼ .053). Differences in n-3 fatty acids, vitamin B6,
folic acid equivalents, vitamin E, and magnesium were robust, taking
the covariates into account, with a 10%e18% lower intake in the sar-
copenic group comparedwith the nonsarcopenic group. Correcting for
the covariates, however, decreased the signiﬁcance of the differences
in protein (g/d), ALA, and selenium intake to the level that the dif-
ference was no longer statistically signiﬁcant. When taking dietary
supplement intake into account, similar nutrients were identiﬁed to
differ between the groups (protein (g/d), n-3 fatty acids, ALA, folic
acid, magnesium). Differences in vitamin B6, vitamin E, and selenium
were, however, no longer signiﬁcant. Differences in n-3 fatty acids
remained robust with a 10% and 19% (n-3 fatty acids expressed as En%
and g/d, respectively) difference between the 2 groups, whereas the
differences in protein (g/d), ALA, folic acid equivalents, and magne-
sium intake were no longer signiﬁcant, based on the analysis taking
the covariates into account. Examples of possible confounding factors
were energy intake and weight (Table 2).
Compared with the nutritional reference values (Appendix
Table A1), most mean nutrient intakes of the total MaSS population
were above the reference values. The mean energy intake of men and
the carbohydrate intakes of men and women were, however, below
the reference values. Although themean protein intakewaswithin the
AMDR of 15e20 En%, 25% of the sarcopenic group and 12% of the
nonsarcopenic group were below the EAR of 0.66 g/kg bw/d.
Compared with the AMDR derived reference value, 74% and 81% were
below 1.2 g/kg bw/d for sarcopenic and nonsarcopenic, respectively.
The mean intakes of EPA, DHA, and of selenium were below the
adequate intakes. Vitamin D intake was considerably lower than the
Assessed for eligibility by phone call 
(n = 282)
No response/not willing to participate (n = 2064)
Drop outs because of illness (n = 9)
Eligibility
Analysis
Data collection Home visits planned (n = 256)
Enrollment Information letters sent (n = 2448)
Informed consents returned (n = 384)
Declined to participate (n = 102)
Not meeting inclusion criteria (n = 26)
• Severe arthritis (n = 2)
• Stroke with evident lingering symptoms (n = 2)
• Disease of the nervous system (n = 2)
• Pacemaker/implantable cardioverter-defibrillator (n = 5)  
• Dementia (n = 3)
• Visually impaired (n = 2)
• Paralyzed (n = 1)
• Wheelchair (n = 1)
• Other (n = 8)
Home visits performed (n = 247)
Analyzed (n = 227)
Excluded from analyses (n = 20)
• Not able to perform grip strength (n = 1)
• MMSE < 24 (n = 9)
• Not able to perform MMSE (n = 1)
• Prostheses/implants on both sides (n = 9)
• FFQ unsuccessful (n = 1)
• Blood drawing unsuccessful (n = 1)
FFQ’s analyzed (n = 226)
Blood samples analyzed (n = 226)
Fig. 1. Flow diagram of the inclusion of MaSS participants, adapted from Mijnarends et al.13
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group below 20 mg/d.
Biochemical Markers of Nutrient Status
Biochemical nutrient levels of the MaSS population and sarcopenic
and nonsarcopenic groups are shown in Table 3. The sarcopenic group
had signiﬁcant, 7%e20% lower levels of EPA, LA, and 25-hydroxyvitamin
D, compared with the nonsarcopenic group. Homocysteine levels were
signiﬁcantly higher in the sarcopenic group, with a 27% higher level
than the nonsarcopenic group. Agewas identiﬁed as a covariate for both
EPA (P ¼ .048) and 25-hydroxyvitamin D (P  .001). Correcting for this
covariate decreased the signiﬁcance of the group differences in EPA and
25-hydroxyvitamin D levels to the level that the difference was no
longer statistically signiﬁcant (P ¼ .108, P ¼ .367, respectively). In
addition, living situationwas identiﬁed as a covariate for EPA (P ¼ .002)
and 25-hydroxyvitamin D (P < .001). As with age, correcting for living
situation decreased the signiﬁcance of the differences in EPA and 25-
hydroxyvitamin D to the levels that the differences were no longer
statistically signiﬁcant (P ¼ .247, P ¼ .426, respectively). The observed
differences in EPA and 25-hydroxyvitamin D between the groups were,
therefore, related to differences in age and living situation. To illustrate,
a signiﬁcant difference was observed for EPA status between the age
categories (P ¼ .024, based on overall test) and living situations
(P < .001, based on overall test) (Figure 2). The same was observed for
25-hydroxyvitamin D status for both the age categories (P < .001) and
living situations (P < .001) (Figure 3). Lower levels of both EPA and 25-
hydroxyvitamin D were present in those aged 86e95 years comparedwith those aged 65e75 years (P ¼ .023, P < .001, respectively). Those
living in residential care had lower levels of EPA and 25-hydroxyvitamin
D compared with those living independently (P < .001, P < .001,
respectively, for overall test).
Although the mean 25-hydroxyvitamin D status of the MaSS par-
ticipants was above the reference value, 51% of the sarcopenic group
and 25% of the nonsarcopenic group had a status below 50 nmol/L. The
sarcopenic older adults had a mean homocysteine level slightly above
the cut-off value of 15 mmol/L. In the sarcopenic group 33% was above
15 mmol/L compared with 16% in the nonsarcopenic group. No major
deﬁciencies were observed for magnesium and a-tocopherol.
Discussion
Our results indicate that sarcopenic older adults had a lower intake
of 5 nutrients (n-3 fatty acids, vitamin B6, folic acid, vitamin E, and
magnesium) compared with nonsarcopenic older adults. When
considering dietary supplement intake,1 nutrient (n-3 fatty acids) was
lower in the sarcopenic older adults. The supplement intake, there-
fore, seems to decrease the intake gap between the sarcopenic and
nonsarcopenic older adults. In addition, 2 biochemical markers (LA
and homocysteine) differed between the 2 groups, with lower LA and
higher homocysteine levels in the sarcopenic older adults. The higher
homocysteine level conﬁrmed the observed lower vitamin B intake in
the sarcopenic group.
Scientiﬁc literature and sarcopenia guidelines indicate that dietary
protein is an important pillar of sarcopenia treatment, as older adults
have an increased need for dietary protein to stimulate their muscle
Table 1
Characteristics of the MaSS Participants
Total (n ¼ 227) Nonsarcopenic (n ¼ 174) Sarcopenic (n ¼ 53) P Value
Sex, n (%)
Male 110 (49%) 85 (49%) 25 (47%) .830*
Female 117 (52%) 89 (51%) 28 (53%)
Age, years 74 (69e79) 72 (68e76) 81 (77e86) <.001y
MNA-SF categories, n (%)
Nonmalnourished 204 (90%) 157 (90%) 47 (89%) .194*
At risk 20 (9%) 16 (9%) 4 (8%)
Malnourished 3 (1%) 1 (1%) 2 (4%)
MNA-SF score 14 (13e14) 14 (13e14) 14 (12e14) .039y
Living situation, n (%)
Independent living 157 (69%) 138 (79%) 19 (36%) <.001*
Home care/assisted living 41 (18%) 24 (14%) 17 (32%)
Residential home 29 (13%) 12 (7%) 17 (32%)
Ethnicity, n (%)
Caucasian 221 (97%) 171 (98%) 50 (94%) .118*
Asian 6 (3%) 3 (2%) 3 (6%)
Smoking status, n (%)
No 79 (35%) 60 (35%) 19 (36%) .983*
Formerly 126 (56%) 97 (56%) 29 (55%)
Yes 22 (10%) 17 (10%) 5 (9%)
Consume alcohol, n (%)
No 26 (12%) 19 (11%) 7 (13%) .657*
Yes 200 (89%) 154 (89%) 46 (87%)
Taking nutritional supplements, n (%)
No 136 (60%) 101 (58%) 35 (66%) .299*
Yes 91 (40%) 73 (42%) 18 (34%)
MMSE score 29 (28e30) 29 (28e30) 28 (28e29) .003y
Number of comorbidities 2.0 (1.0e3.0) 1.0 (1.0e3.0) 3.0 (1.0e4.0) <.001y
Body composition
Weight, kg 76.0 (67.7e83.2) 77.0 (69.1e83.7) 71.5 (59.3e79.5) .002y
Height, m 1.67 (0.09) 1.68 (0.09) 1.64 (0.09) .007z
BMI, kg/m2 26.6 (24.6e29.4) 26.8 (24.7e29.6) 26.1 (23.5e28.2) .048y
SMM, kg 23.5 (17.1e28.4) 24.0 (17.7e28.8) 22.7 (15.2e26.3) .003y
SMI, kg/m2 8.3 (6.7e9.5) 8.4 (6.9e9.5) 7.9 (6.1e9.4) .020y
Physical function
Hand grip strength, kg 26.4 (9.7) 28.7 (9.2) 18.8 (7.1) <.001z
Gait speed, m/s 1.01 (0.27) 1.08 (0.24) 0.76 (0.23) <.001z
Physical activity, kcal/week 1893 (636e3431) 2230 (1074e3646) 765 (246e2083) <.001y
SD, standard deviation.
Data are presented as n (%), mean (SD) or median (Q1-Q3).
*c2 test.
yNonparametric Wilcoxon rank sum test.
z2 independent samples t-test.
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protein intake (in g/d) was found between sarcopenic and non-
sarcopenic older adults. The multiple regression analysis indicated
that the difference in protein intake is related to the difference in,
amongst others, energy intake and MNA-SF score. A low energy
intake can increase the risk of a low protein intake, and adequate daily
protein intake is, therefore, important to monitor. The relative mea-
sure of protein intake adjusted for bodyweight (in g/kg bw/d) might
be less appropriate for detecting differences between sarcopenic and
nonsarcopenic older adults, when groups differ in bodyweight and
SMI, as was the case in this study.
N-3 fatty acids are mentioned as part of an integrated manage-
ment of sarcopenia, combined with physical activity, protein, and
vitamin D.42 We observed a signiﬁcant difference in RBC EPA levels
between the sarcopenic and nonsarcopenic groups. The analysis
taking into account possible covariates and the subgroup analysis,
however, indicate that this difference was related to a difference in
age and living situation, rather than primarily because of the presence
of sarcopenia. This decrease in RBC EPA levels with age was also
observed in another study, with decreasing levels after the age of
70.43 Overall, the RBC n-3 and n-6 fatty acids proﬁle in the MaSS
population were comparable to a previous study in French
community-dwelling older adults.44
We observed a lower intake of vitamin B6 and folic acid and higher
homocysteine level in the sarcopenic older adults compared with thenonsarcopenic group. Vitamins B6, B12, and folate are cofactors of
homocysteine metabolism and deﬁciencies of these vitamins can
result in elevated homocysteine levels.45 It has been hypothesized that
these higher homocysteine levels may increase oxidative stress and
muscle protein degradation and negatively impact muscle strength
and physical functioning in older adults.26,46
Although the dietary vitamin D intake was not signiﬁcantly
different between the groups (P ¼ .053), we did observe a signiﬁ-
cantly lower 25-hydroxyvitamin D level in the sarcopenic group. This
might indicate that our sarcopenic and nonsarcopenic groups
differed in their sun exposure. The sarcopenic older adults in our
study received home care more frequently than the nonsarcopenic
older adults. This may indicate a higher level of dependence, less
time spend outdoors, and, thus, less sun exposure. The multiple
regression analysis correcting for possible covariates and subsequent
subgroup analysis demonstrated that the difference in 25-
hydroxyvitamin D was related to age and living situation. This may
indicate that these factors play a role in the observed group differ-
ence, rather than primarily the presence of sarcopenia. The
discrepancy between the low (<20 mg) vitamin D intake and the
mean adequate (>50 nmol/L) 25-hydroxyvitamin D levels illustrates
the importance of biomarker assessments when interpreting vitamin
D data. Comparable results were found in the B-Vitamins for Pre-
vention of Osteoporotic Fractures Study,47 in which a total (including
supplements) vitamin D intake of 5.2 mg/d was found for those with a
Table 2
Total Daily Nutrient Intake, Including Dietary and Supplement Intake of the Total MaSS Population, and for the Sarcopenic and Nonsarcopenic Participants Separately
Supplement
Usersy
Dietary Intake Total Energy and Nutrient Intake*
Total n ¼ 226 Nonsarcopenic n ¼ 173 Sarcopenic n ¼ 53 P Valuez Nonsarcopenic n ¼ 167x Sarcopenic n ¼ 53x P Valuez
Energy, MJ 7.6 (2.2) 7.7 (2.2) 7.2 (2.2) .133 7.8 (2.2) 7.2 (2.2) .119
Energy, kcal 1818 (526) 1847 (525) 1723 (521) .133 1853 (527) 1724 (521) .119
Carbohydrate, g 184 (57) 187 (56) 176 (61) .246 188 (56) 177 (61) .221
Carbohydrate, En% 41 (6) 41 (6) 41 (7) .691 41 (6) 41 (7) .696
Protein, g 73 (21) 74 (20) 68 (22) .048k 74 (20) 68 (22) .048{
Protein, g/kg bw 0.98 (0.31) 0.98 (0.29) 0.98 (0.36) .915 0.97 (0.27) 0.98 (0.36) .835
Protein, En% 16 (3) 16 (3) 16 (3) .186 16 (3) 16 (3) .226
Fat, g 72 (27) 74 (28) 68 (25) .222 74 (28) 68 (25) .214
Fat, En% 35 (5) 35 (5) 36 (6) .909 35 (5) 36 (6) .861
Alcohol, g 13 (16) 13 (16) 13 (16) .818 13 (16) 13 (16) .818
Alcohol, En% 4.9 (5.9) 4.9 (5.7) 5.1 (6.6) .765 5 (6) 5 (7) .839
n-3 fatty acids, g 5 2.0 (0.8) 2.0 (0.8) 1.7 (0.7) .007 2.1 (0.8) 1.7 (0.7) .005
n-3 fatty acids, En% 1.0 (0.3) 1.0 (0.2) 0.9 (0.3) .026 1.0 (0.3) 0.9 (0.3) .022
ALA, 18:3n-3, g 1 1.67 (0.69) 1.73 (0.71) 1.47 (0.59) .019# 1.73 (0.72) 1.47 (0.59) .018**
EPA, 20:5n-3, g 14 0.08 (0.07) 0.09 (0.08) 0.07 (0.06) .076 0.10 (0.11) 0.08 (0.07) .089
DHA, 22:6n-3, g 13 0.11 (0.11) 0.12 (0.12) 0.09 (0.09) .101 0.14 (0.14) 0.10 (0.09) .064
Vitamin B6, mg 54 1.6 (0.5) 1.7 (0.5) 1.4 (0.5) .005 2.9 (8.0) 2.4 (3.8) .679
Vitamin B12, mg 54 5.0 (2.8) 5.2 (3.0) 4.4 (2.1) .079 10.7 (45.8) 6.9 (13.9) .550
Folic acid equivalents, mg 46 305 (112) 319 (110) 260 (104) <.001 375 (167) 312 (160) .016yy
Vitamin C, mg 59 116 (59) 119 (58) 104 (61) .103 179 (191) 178 (227) .966
Vitamin D, mg 52 3.6 (1.5) 3.7 (1.6) 3.3 (1.3) .053 5.2 (3.6) 4.5 (3.0) .197
Vitamin E, mg 53 13 (5) 13 (5) 11 (4) .005 18 (19) 19 (30) .689
Calcium, mg 46 869 (395) 874 (406) 852 (358) .726 903 (402) 894 (383) .884
Magnesium, mg 52 308 (93) 317 (92) 279 (92) .009 350 (125) 305 (132) .024zz
Selenium, mg 49 43 (13) 44 (13) 40 (13) .020xx 56 (29) 54 (32) .632
Zinc, mg 51 10 (3) 10 (3) 9 (3) .094 12 (5) 11 (6) .576
k, {, #, **, yy, zz, xx No longer statistically signiﬁcant following the multiple regression analysis.
Data are presented as mean (SD).
*Total nutrient intake includes both dietary and supplement nutrient intake.
yNumber of subjects consuming micronutrients via a dietary supplement.
zComparison sarcopenic vs nonsarcopenic (2 independent samples t-test).
xNumber of participants for EPA and DHA (nonsarcopenic: n ¼ 166, sarcopenic: n ¼ 53) and alcohol (nonsarcopenic: n ¼ 173. sarcopenic: n ¼ 53).
kSigniﬁcant covariates: MNA-SF, ethnicity, alcohol consumption, MMSE score, comorbidities, weight, height, BMI, physical activity, energy intake.
{Signiﬁcant covariates: MNA-SF, ethnicity, smoking, alcohol consumption, MMSE score, comorbidities, weight, height, BMI, physical activity, energy intake.
#Signiﬁcant covariates: weight and height, physical activity, energy intake.
**Signiﬁcant covariates: weight and height, physical activity, energy intake.
yySigniﬁcant covariates: physical activity, energy intake.
zzSigniﬁcant covariates: age, living situation, height, physical activity, energy intake.
xxSigniﬁcant covariates: MMSE score, weight, height, physical activity, energy intake.
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the B-PROOF also observed a decrease in 25-hydroxyvitamin D with
age, which is in line with our multiple regression and subgroup an-
alyses. Overall, only 24% of the MaSS population took dietaryTable 3
Biochemical Nutrient Status of the Total MaSS Population and for the Sarcopenic and
Nonsarcopenic Participants Separately
Total n ¼ 226* Nonsarcopenic
n ¼ 173*
Sarcopenic
n ¼ 53*
P
Valuey
25-hydroxyvitamin D,
nmol/l
66.8 (31.0) 70.1 (30.3) 56.2 (31.3) .004z
Magnesium, mmol/l 0.87 (0.08) 0.87 (0.08) 0.87 (0.08) .941
n-3 fatty acids, % 7.10 (1.15) 7.14 (1.19) 6.98 (1.03) .390
EPA, 20:5n-3, % 0.91 (0.36) 0.94 (0.38) 0.79 (0.27) .007z
DPA, 22:5n-3, % 2.13 (0.25) 2.13 (0.25) 2.12 (0.27) .860
DHA, 22:6n-3, % 3.80 (0.81) 3.80 (0.83) 3.81 (0.74) .964
n-6 fatty acids, % 28.0 (1.7) 28.0 (1.7) 27.9 (1.6) .583
LA, 18:2n-6, % 10.4 (1.6) 10.6 (1.6) 9.9 (1.6) .016
AA, 20:4n-6, % 12.7 (1.3) 12.6 (1.3) 12.9 (1.5) .196
Homocysteine, mmol/l 12.8 (5.4) 12.1 (4.2) 15.2 (7.9) <.001
a-tocopherol/cholesterol,
mmol/mmol
6.87 (1.15) 6.86 (1.18) 6.92 (1.06) .730
Data are presented as mean (SD).
*Number of participants for n-3 fatty acids, EPA, DPA, DHA, n-6 fatty acids, LA, AA,
homocysteine, a-tocopherol/cholesterol: total n ¼ 225, nonsarcopenic n ¼ 173,
sarcopenic n ¼ 52.
yComparison sarcopenic vs nonsarcopenic (2 independent samples t-test).
zNo longer statistically signiﬁcant following the multiple regression analysis,
signiﬁcant covariates are age and living situation.supplements containing vitamin D, in contrast to the Dutch national
recommendation that advices vitamin D supplements for older
adults.48 Both the sarcopenic and nonsarcopenic group had average
25-hydroxyvitamin D levels above 50 nmol/L, however, 51% of the
sarcopenic group and 25% of the nonsarcopenic group had a deﬁcient
status.48 Part of the overall MaSS participants are, therefore, at risk of
loss of muscle mass, as the Longitudinal Aging Study Amsterdam
cohort27 indicates that older adults with serum levels below 25 nmol
and between 25 and 50 nmol/L are at an increased risk of loss of
appendicular skeletal muscle mass compared with those with levels
equal or above 50 nmol/L.
The sarcopenic participants differed in their vitamin E intake
compared with the nonsarcopenic group, however, no signiﬁcant
difference was observed in the a-tocopherol to total cholesterol ratio.
Although a linear relationship has been reported for intake and
plasma levels, the strength of this relationship varies among studies,49
which may explain the observed discrepancy in our results. We also
observed a lower selenium intake among the sarcopenic older adults.
Vitamin E and selenium might act as antioxidants, addressing oxida-
tive damage. Oxidative damage has been proposed as one of the
contributors to sarcopenia, through DNA, lipid and protein damage,
and subsequent muscle atrophy.50,51
Magnesium intake differed signiﬁcantly between the sarcopenic
group compared with the nonsarcopenic group, however, this was
not reﬂected in a difference in serum magnesium levels. Serum
magnesium levels are a useful marker for major deﬁciencies but
may not be sensitive to small differences in magnesium intake.
Fig. 2. (A) Box plot representing the RBC EPA level (%) of the total MaSS population, per
age category. The boxes represent the interquartile range (IQR), with the median
indicated as a bar within the box. The whiskers represent 1.5 times the IQR, outliers are
indicated as circles, and extreme outliers with a star. Different letters indicate signif-
icant differences in groupmean EPA levels (P < .05, 1-way analysis of variance (ANOVA)
with Tukey all-pairs comparison). (B) Box plot representing the RBC EPA level (%) of the
total MaSS population, per living situation. The boxes represent the IQR, with the
median indicated as a bar within the box. The whiskers represent 1.5 times the IQR,
outliers are indicated as circles and extreme outliers with a star. Different letters
indicate signiﬁcant differences in group mean EPA levels (P < .01, 1-way ANOVA with
Tukey all-pairs comparison).
Fig. 3. (A) Box plot representing the 25-hydroxyvitamin D levels of the total MaSS
population, per age category. The boxes represent the IQR, with the median indicated
as a bar within the box. The whiskers represent 1.5 times the IQR, outliers are indicated
as circles, and extreme outliers with a star. Different letters indicate signiﬁcant dif-
ferences in group mean 25-hydroxyvitamin D levels (P < .01, 1-way ANOVAwith Tukey
all-pairs comparison). (B) Box plot representing the 25-hydroxyvitamin D levels of the
total MaSS population, per living situation. The boxes represent the IQR, with the
median indicated as a bar within the box. The whiskers represent 1.5 times the IQR,
outliers are indicated as circles and extreme outliers with a star. Different letters
indicate signiﬁcant differences in group mean 25-hydroxyvitamin D levels (P < .01, 1-
way ANOVA with Tukey all-pairs comparison).
S. ter Borg et al. / JAMDA 17 (2016) 393e401 399Magnesium levels are kept constant52 and are strictly regulated by
urinary excretion, bone stores, and gastrointestinal tract,49 which
may explain why the difference in magnesium intake was not
reﬂected by a difference in the serum magnesium levels between
the 2 groups.
Energy intake did not differ signiﬁcantly between the sarcopenic
and nonsarcopenic groups in the present study, but was identiﬁed as a
covariate for some of the observed nutrient intake differences. This
indicates that there could be a difference in diet quality between
sarcopenic and nonsarcopenic older adults in the MaSS population,
rather than an overall lower food intake. Among Iranian older adults,
adherence to theMediterranean diet was associatedwith a lower odds
of sarcopenia,12 which illustrated the importance of diet quality. Un-
derstanding the food pattern and food choices of sarcopenic older
adults would, therefore, be of added value. Although we did not
observe signiﬁcant differences in energy intake between the 2 groups,
it is important to monitor energy intake as anorexia is associated withsarcopenia,53 and low energy intakes are frequently reported among
community-dwelling older adults.54
Compared with the nutritional reference values, a low energy
intake in the MaSS men was observed. We, however, do not expect
that the overall MaSS populationwas suffering from an energy deﬁcit.
Both groups had a maximumMNA-SF score of 14 with 1% of the total
population being malnourished and 9% at risk of malnutrition. The
mean BMI of the MaSS population was 27 kg/m2. The nutritional
reference value based on a physical activity level of 1.6, which rep-
resents a light active lifestyle, may have overestimated their actual
energy need.
The nutrient intake of the MaSS population is comparable to that
of the Dutch National Food Survey (DNFCS)55 and recent systematic
literature reviews54,56 (Appendix Table A1). Only 1 cohort study
(KNHANES)10,11 previously investigated the difference in nutrient
intake (ie, energy, protein, carbohydrate, vitamin D, and calcium)
between, Korean, sarcopenic, and nonsarcopenic older adults. The
S. ter Borg et al. / JAMDA 17 (2016) 393e401400KNHANES found differences in energy, carbohydrate, and calcium
intakes between sarcopenic and nonsarcopenic older adults.
Although we observed slightly lower carbohydrate intakes in the
sarcopenic group, the difference between the 2 groups was not sig-
niﬁcant. We also did not observe signiﬁcant differences for calcium
intake. Calcium intake in the MaSS population was considerably
higher compared with the KNHANES cohort (901 mg vs 410 mg,
respectively), indicating that the MaSS older adults had adequate
access to calcium-rich foods. Differences in sarcopenia deﬁnition
(appendicular skeletal muscle mass to body weight ratio of at least 2
standard deviations below the mean for young adults), methodology,
and participant characteristics may explain the different ﬁndings in
the Korean and the MaSS cohorts.
Several strengths and limitations need to be mentioned. One of
the strengths of the present study is the comprehensive assessment of
dietary and supplement intake and biomarker nutrient status, as well
as sarcopenia determinants. It, therefore, provides a more complete
overview than most other publications that focus on 1 single nutrient
and a speciﬁc muscle parameter. The MaSS population was recruited
in Maastricht and is a representative sample (based on age, sex,
cognition, BMI, smoking) of healthy Dutch community-dwelling older
adults compared with the DNFCS.55 The analysis of dietary supple-
ment intake is of added value, as for certain nutrients the supple-
ments contributed to up to one-third of their total nutrient intake and
may have affected their nutritional status and subsequently their
health (eg, sarcopenia). In addition, the inclusion of biochemical
nutrient markers and covariates with the multiple regression analysis
has strengthened the conclusion of the present study.
There are also several limitations that should be considered when
interpreting the results of the present study. An FFQ was used to
assess the habitual nutrient intake. Although it is a valid method to
assess habitual intake, an older adult population may have difﬁ-
culties with recalling all foods and community-dwelling older adults
are known to underreport their energy intakes by 10%-15%.55,57 Our
results on dietary intake are, however, in line with the DNFCS,55
which used two 24-hour dietary recalls to assess intake. The
observed differences in intake may be related to differences in
underreporting between sarcopenic and nonsarcopenic older adults.
We, however, do not have grounds to believe that those suffering
from sarcopenia differ in their reporting from nonsarcopenic older
adults. As we use the FFQ, we might have underestimated the vari-
ance in dietary intake of our MaSS population. In addition, we were
not able to assess the prevalence of underreporters. Including sup-
plement intake increased the nutrient intake variation, which may
have inﬂuenced our ability to detect signiﬁcant differences between
the groups. The statistical method used to correct for possible con-
founding factors assumed a linear relationship between the depen-
dent variable and the possible confounding factor. The validity of
these models may depend onwhether this assumption was justiﬁed.
As the present study had a cross-sectional design, no conclusions can
be made on a causal relationship between the observed nutrient
differences and sarcopenia. Longitudinal studies may provide further
insight whether the observed differences in nutrient intake can lead
to changes in (the determinants of) sarcopenia.
Conclusions
Sarcopenic older adults had a 10%e18% lower intake of 5 nutrients
(n-3 fatty acids, vitamin B6, folic acid, vitamin E, and magnesium)
compared with nonsarcopenic older adults. For the 2 biochemical
status markers, LA and homocysteine, a 7% and 27% difference was
observed, respectively. Dietary supplement intake seems to reduce the
gap for some of these nutrients. Targeted nutritional interventionmay,
therefore, improve the nutrient intake and biochemical nutrient sta-
tus of sarcopenic older adults.Acknowledgments
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